Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm

1. Barrio, S.
2. Gallardo, M.
3. Arenas, A.
4. Ayala, R.
5. Rapado, I.
6. Rueda, D.
7. Jimenez, A.
8. Albizua, E.
9. Burgaleta, C.
10. Gilsanz, F.
11. Martinez-Lopez, J.